Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing innovative products for unmet medical needs. A key strength is its robust liquidity, evidenced by a current ratio of 23.98 and no debt, indicating strong financial stability. However, concerns arise from negative returns on equity and assets, suggesting operational challenges. The recent 6.48% decline in stock price may reflect market skepticism about its growth prospects, despite a solid market cap of $701.91M. Overall, while the company has a strong balance sheet, its profitability metrics warrant close attention.
Loading financial metrics...
Company posted a loss of $-32.7M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $24.8M over the last year.
Fortress balance sheet: cash covers total debt 521×, providing significant financial flexibility.
Excellent liquidity with current ratio of 24.0x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)